文献类型：期刊文献

中文题名：奥马环素治疗老年慢性阻塞性肺疾病合并社区获得性细菌性肺炎患者的临床观察

英文题名：Clinical observation of omadacycline in treating elderly patients with chronic obstructive pulmonary disease complicated by community-acquired bacterial pneumonia

作者：杨飞燕[1];杨国彪[1];张娅[1];杨剑烨[1];徐萌敏[1]

机构：[1]绍兴文理学院附属医院(绍兴市立医院)呼吸与危重症医学科二病区,浙江绍兴312000

年份：2025

卷号：29

期号：8

起止页码：1385

中文期刊名：药学前沿

外文期刊名：China Pharmacist

基金：浙江省医药卫生科技计划项目(2025KY1700)。

语种：中文

中文关键词：奥马环素;慢性阻塞性肺疾病;社区获得性细菌性肺炎;临床效果

外文关键词：Omadacycline;Chronic obstructive pulmonary disease;Community-acquired bacterial pneumonia;Clinical efficacy

中文摘要：目的观察奥马环素治疗老年慢性阻塞性肺疾病(COPD)合并社区获得性细菌性肺炎(CABP)患者的临床效果。方法回顾性分析2023年6月至2024年12月在绍兴市立医院治疗的老年COPD合并CABP患者临床资料,根据治疗药物不同,分为观察组(奥马环素治疗)和对照组(其他一线药物治疗),比较两组患者的临床资料。结果共纳入100例患者,观察组39例,对照组61例。两组患者治疗前C反应蛋白(CRP)、降钙素原(PCT)、白细胞计数(WBC)、白细胞介素6(IL-6)、用力肺活量(FVC)、第1秒用力呼气量(FEV1)、FEV1/FVC及FEV1占预计值百分比水平差异无统计学意义(P>0.05)。治疗后观察组CRP、PCT、WBC及IL-6水平均显著低于对照组(P<0.05),FVC、FEV1、FEV1/FVC及FEV1占预计值百分比均显著高于对照组(P<0.05),咳嗽消退时间、咳痰消退时间、发热消退时间、肺部啰音消退时间、喘息消退时间及住院时间均显著低于对照组(P<0.05),总有效率显著高于对照组(94.87%vs.85.24%,P<0.05)。治疗后两组各不良反应差异无统计学意义(P>0.05)。结论奥马环素治疗老年COPD合并CABP患者具有一定临床效果,且安全性良好。

外文摘要：Objective To observe the clinical efficacy of omadacycline in treating elderly patients with chronic obstructive pulmonary disease(COPD)complicated by community-acquired bacterial pneumonia(CABP).Methods The clinical data of elderly patients with COPD and CABP treated in Shaoxing Municipal Hospital from June 2023 to December 2024 were retrospectively analyzed.According to the different treatment drugs,they were divided into an observation group(omadacycline treatment)and a control group(other first-line drug treatment),and the clinical data of the two groups of patients were compared.Results A total of 100 patients were enrolled,with 39 in the observation group and 61 in the control group.Before treatment,there were no statistically significant differences in C-reactive protein(CRP),procalcitonin(PCT),white blood cell count(WBC),interleukin-6(IL-6),forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC ratio,and the percentage that FEV1 accounts for in the predicted value between the two groups(P>0.05).After treatment,the observation group showed significantly lower levels of CRP,PCT,WBC,and IL-6 than the control group(P<0.05),and higher levels of FVC,FEV1,FEV1/FVC ratio,and the percentage that FEV1 accounts for in the predicted value(P<0.05).The observation group also had significantly shorter times for cough resolution,sputum resolution,fever resolution,lung rale resolution,dyspnea resolution,and hospital stay(P<0.05),and a significantly higher total effective rate(94.87%vs.85.24%,P<0.05).After treatment,there were no statistically significant differences in adverse reactions between the two groups(P>0.05).Conclusion Omadacycline has certain clinical effects in the treatment of elderly patients with COPD and CABP with good safety.